Erratum: The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma

Article metrics

Correction to: British Journal of Cancer (2017) 116, 1402–1407. doi:https://doi.org/10.1038/bjc.2017.119; published online 25 April 2017

The authors would like to add Dr Rose Parkinson to the author list. She now appears in the author list, and her affiliation is also provided, above.

The authors would like to change the acknowledgments to the following:

‘We thank the patients and their families for participating in this study and the clinical staff at Johns Hopkins and MD Anderson Cancer Center for their clinical care and data collection.’

The authors would also like to correct Table 2; the updated table is shown below. To reflect the updated table, the authors would also like to make changes to the ‘Adverse events’ section of the Results. The second sentence of the second paragraph should now read:

‘Treatment-related toxicities were predominantly of mild or moderate severity, with the most common events including rash (76% of patients), hypertension (60%), nausea or vomiting (64%), fatigue (60%), diarrhoea (60%), and thrombocytopenia (40%).’

Despite the changes to Table 2 and the associated text, the authors state that the conclusions put forth in this article, including the safety of this regimen, remain unchanged.

Table 2 Treatment-related adverse events occurring in two or more participants, and all grade ¾ treatment-related adverse events

Change history

  • 23 January 2018

    This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication

Author information

Additional information

This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License.

The online version of the original article can be found at https://doi.org/10.1038/bjc.2017.119

Rights and permissions

From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Shroff, R., Yarchoan, M., O'Connor, A. et al. Erratum: The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma. Br J Cancer 118, e2 (2018) doi:10.1038/bjc.2017.418

Download citation